Skip to main content
SpringerLink
Log in

Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs

  • Chapter
Principles of Molecular Oncology

  • 1197 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. 1. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55:10–30.

    Article  PubMed  Google Scholar 

  2. 2. Schiller JH, Harrinton D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.

    Article  PubMed  CAS  Google Scholar 

  3. 3. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001;19:3210–3218.

    PubMed  CAS  Google Scholar 

  4. 4. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 2002;1:300–308

    Article  PubMed  CAS  Google Scholar 

  5. Phillips DH. Allison MR (ed) Macmillan, London. The formation of DNA adducts. The cancer handbook. In: Nature Publishing Group 2002:293–307.

    Google Scholar 

  6. 6. Wei Q, Cheng L, Hong WK Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996; 90:1614–1618.

    Google Scholar 

  7. 7. Wei Q, Cheng L, Amos CI et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiological study. J Natl Cancer Inst 2000; 92:1764–1772.

    Article  PubMed  CAS  Google Scholar 

  8. 8. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Nat Cancer Inst 2002;94:1091–1099.

    PubMed  Google Scholar 

  9. 9. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001;291:1284–1289.

    Article  PubMed  CAS  Google Scholar 

  10. 10. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331–344.

    Article  PubMed  CAS  Google Scholar 

  11. 11. De Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis 2000;21:453–460.

    Article  PubMed  Google Scholar 

  12. 12. De Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev 1999;13:768–785.

    Article  PubMed  Google Scholar 

  13. 13. Hasty P, Campisi J, Hoeijmakers J, Van Steeg H, Vijg J. Aging and genome maintenance: lessons from the mouse? Science 2003;299:1355–1359.

    Article  PubMed  CAS  Google Scholar 

  14. 14. Houtsmuller AB, Rademakers S, Nigg AL, Hoogstrten D, Hoeijmakers J, Vermeulen W. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 1999;284:958–961.

    Article  PubMed  CAS  Google Scholar 

  15. 15. Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in ovarian cancer cells. Anticancer Res 2000;20:645–652.

    PubMed  CAS  Google Scholar 

  16. 16. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978–983.

    Article  PubMed  Google Scholar 

  17. 17. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309–316.

    PubMed  CAS  Google Scholar 

  18. 18. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512–1517.

    Article  PubMed  CAS  Google Scholar 

  19. 19. Warnecke-eberz U, Metzger R Miyazono F, et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10:3794–3799.

    Article  PubMed  CAS  Google Scholar 

  20. 20. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and Thymidylate Synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298–4304.

    PubMed  CAS  Google Scholar 

  21. 21. Lord R, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286–2291.

    PubMed  CAS  Google Scholar 

  22. 22. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318–1325.

    Article  PubMed  CAS  Google Scholar 

  23. 23. Rosell R, Cobo M, Isla I, et al. ERCC1 mRNA-based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer. J Clin Oncol 2005;23:Suppl16:A7002.abstract.

    Google Scholar 

  24. 24. Olaussen KA, Dunant A, Fourte P, et al. ERCC1 expression and benefit of adjuvant cisplatin-based chemotherapy in patients with resected non-small-cell lung cancer. N Engl J Med 2006;355:983–991.

    Article  PubMed  CAS  Google Scholar 

  25. 25. Gaboli M, Kotsi PA, Gurrieri C, et al. Mzf1 controls cell proliferation and tumorogenesis. Genes Dev 2001;15:1625–1630.

    Article  PubMed  CAS  Google Scholar 

  26. 26. Yan QW, Reed E, Zhong XS et al. MZF1 posseses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 2006;71:761–771.

    Article  PubMed  CAS  Google Scholar 

  27. 27. Miki Y, Swensen J, Shattuck-Eidens D. A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science 1994;266:66–71

    Article  PubMed  CAS  Google Scholar 

  28. 28. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995;9:444–450.

    Article  PubMed  CAS  Google Scholar 

  29. 29. Seery LT, Knowlden JM, Gee JM, et al. BRCA1 expression level predicts distant metastasis of sporadic breast cancers. Int J Cancer 1999;84:258–262.

    Article  PubMed  CAS  Google Scholar 

  30. 30. Rice J, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000;21:1761–1765.

    Article  PubMed  CAS  Google Scholar 

  31. 31. Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 2001;477:131–153.

    PubMed  CAS  Google Scholar 

  32. 32. Gowen LC, Avrutskaya AV, Latour AM, Doller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009–1012.

    Article  PubMed  CAS  Google Scholar 

  33. 33. Quinn JE, Dennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221–6228.

    PubMed  CAS  Google Scholar 

  34. 34. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285–1291.

    Article  PubMed  CAS  Google Scholar 

  35. 35. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003;22:1169–1173.

    PubMed  CAS  Google Scholar 

  36. 36. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001;95:255–259.

    Article  PubMed  CAS  Google Scholar 

  37. 37. Tarón M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004;20:2443–2449.

    Article  CAS  Google Scholar 

  38. 38. Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 1992;17: 119–123.

    Article  PubMed  CAS  Google Scholar 

  39. 39. Zhou B, Liu X, Mo X, et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 2003;63:6583–6594.

    PubMed  CAS  Google Scholar 

  40. 40. Huang P, Chubb S, Hertel LW, Grindey GB, PlunketT W. Action of 2′2′-Difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110–6117.

    PubMed  CAS  Google Scholar 

  41. 41. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999;59:4204–4207.

    PubMed  CAS  Google Scholar 

  42. 42. Dumontet C, Fabianowska-Majewsda K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999;106:78–85.

    Article  PubMed  CAS  Google Scholar 

  43. 43. Davidson J, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004;64:3761–3766.

    Article  PubMed  CAS  Google Scholar 

  44. 44. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall survival and disease-free survival in patients with non-small cell lung cancer. J Clin Oncol 2004;22:1878–1885.

    Article  PubMed  CAS  Google Scholar 

  45. 45. Scagliotti G, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002;20:4285–4291.

    Article  PubMed  CAS  Google Scholar 

  46. 46. Rosell R, Scagliotti G, Danenber KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003;22:3548–3553.

    Article  PubMed  CAS  Google Scholar 

  47. 47. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J Clin Oncol 2003;21:3207–3213.

    Article  PubMed  CAS  Google Scholar 

  48. 48. Rosell R, Danenberg KD, Alberola V, et al.: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318–1325.

    Article  PubMed  CAS  Google Scholar 

  49. 49. Bepler G, Sharma A, Greenberg A, et al. Prospective evaluation of RRM1 as a predictor of response to gemcitabine/carboplatin in non-small cell lung cancer. J Clin Oncol 2006;24:Suppl18:A.7054.abstract.

    Google Scholar 

  50. 50. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004;90:747–751.

    Article  PubMed  CAS  Google Scholar 

  51. 51. Zhu J, Spitz MR, Christopher IA, Lin J, Schabath, Wu X. An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res 2004;64:2251–2257.

    Article  PubMed  CAS  Google Scholar 

  52. 52. Hoeijmakers JH, Egly JM, Vermeulen W. TFHIIH: a key component in multiple DNA transactions. Curr Opin Genet Dev 1996:6:26–33.

    Article  PubMed  CAS  Google Scholar 

  53. 53. Eveno E, Bourre F, Quilliet X, et al. Different removal of ultraviolet photoproducts in genetically related xeroderma pigmentosum and trichothiodystrophy diseases. Cancer Res 1995;5:4325–4332.

    Google Scholar 

  54. 54. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphism in lung cancer patients. Cancer Res 2001;61:1354–1357.

    PubMed  CAS  Google Scholar 

  55. 55. Zhou W, Liu G, Miller AP, et al. Gene-environment interaction for ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res 2002;62:1377–1381.

    PubMed  CAS  Google Scholar 

  56. 56. Hou S, Falt S, Angelini S, et al The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002;23:599–603.

    Article  PubMed  CAS  Google Scholar 

  57. 57. Park D, Stoehlmacher J, Zhan W, Tsao-Wei D, Groshen S, Lenz HJ. A xeroderma pigmentosum group D gene polymorphisms predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001;61:8654–8658.

    PubMed  CAS  Google Scholar 

  58. 58. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594–2601.

    Article  PubMed  CAS  Google Scholar 

  59. 59. De las Peñas R, Sanchez-Ronco M, Alverola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol. 2006;17:668–675.

    Article  Google Scholar 

  60. 60. Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:491–496.

    Article  PubMed  CAS  Google Scholar 

  61. 61. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor fro clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162–166.

    PubMed  Google Scholar 

  62. 62. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clinical Cancer Res 2004;10:4939–4944.

    Article  CAS  Google Scholar 

  63. 63. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194–1203.

    Article  PubMed  CAS  Google Scholar 

  64. 64. Tarón M, Alverola V, López-Vivanco G, et al. Excision repair cross-complementing group1 (ERCC1) single nucleotide polymorphisms and survival in cisplatin/docetaxel-treated stage IV non-small-cell lung cancer patients: a Spanish Lung Cancer Group Study. J Clin Oncol 2006;24:Suppl18:A7053.

    Google Scholar 

  65. 65. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005;11:1534–1538.

    Article  PubMed  CAS  Google Scholar 

  66. 66. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32) P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001;22:1437–1445.

    Article  PubMed  CAS  Google Scholar 

  67. 67. Rosell R, Alberola V, Camps C, et al. Clinical outcome of gemcitabine/cisplatin versus docetaxel/cisplatin treated stage IV non-small-cell lung cancer patients according to X-ray repair cross-complementing group 3 polymorphism and age. J Clin Oncol 2006;24:Suppl18:A7055.abstract.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Juan Canalejo Hospital, A Coruña, Spain

    Rosario García-Campelo MD, PhD & Rafael Rosell MD

  2. Catalan Institute of Oncology, Barcelona, Spain

    Miquel Tarón PhD, Itziar De Aguirre MD & Pedro Méndez MD

Authors
  1. Rosario García-Campelo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miquel Tarón PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Itziar De Aguirre MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pedro Méndez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafael Rosell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hospital General of Granollers, Barcelona, Spain

    Miguel H. Bronchud MD, PhD

  2. MA Foote Associates, Westlake Village, CA, USA

    Mary Ann Foote PhD

  3. National Cancer Institute, Bethesda, Maryland

    Giuseppe Giaccone MD, PhD

  4. University of Chicago Medical Center, Chicago, IL, USA

    Olufunmilayo Olopade MD

  5. CRC Center for Cancer Therapeutics, Surrey, UK

    Paul Workman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc.

About this chapter

Cite this chapter

García-Campelo, R., Tarón, M., Aguirre, I.D., Méndez, P., Rosell, R. (2008). Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs. In: Bronchud, M.H., Foote, M.A., Giaccone, G., Olopade, O., Workman, P. (eds) Principles of Molecular Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-470-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-470-4_19

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-25-1

  • Online ISBN: 978-1-59745-470-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation